Fierce Pharma
JANUARY 3, 2024
Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024. As the J.P. | As the J.P.
Fierce Pharma
JANUARY 8, 2024
Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. Morgan Healthcare Conference. | In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 27, 2024
In June, when the Supreme Court voted 6-3 to overturn the Chevron doctrine, it brought significant impact for the healthcare industry and federal regulators like the FDA and the Centers for Medicare & Medicaid Services. An expert recently discussed the ramifications of the ruling during a Fierce Pharma podcast interview.
Fierce Pharma
JUNE 11, 2024
Amid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent splashes.
Fierce Pharma
FEBRUARY 27, 2024
A seismic shift has occurred in the healthcare landscape. Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support.
Fierce Pharma
NOVEMBER 5, 2024
works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. As the U.K. Flush with a 50 million pound sterling ($65 million) joint investment deal from the U.K.,
Fierce Pharma
SEPTEMBER 19, 2023
Artificial intelligence (AI) has enormous potential in healthcare, but all too often, it gets misunderstood. With the right infrastructure, intelligent tools stand to not only process data but also improve clinical decision-making—helping find more patients for biopharma companies, and faster, too.
Expert insights. Personalized for you.
346 
Let's personalize your content